<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "6: focused on product development", fill: "#ccf"},
{source: "6: focused on product development", target: "6: revenues utilizing", fill: "#ccf"},
{source: "6: revenues utilizing", target: "6: technology", fill: "#ccf"},
{source: "6: focused on product development", target: "9: significant clinical", fill: "#4b3621"},
{source: "9: significant clinical", target: "9: development", fill: "#4b3621"},
{source: "9: development", target: "9: laboratory testing", fill: "#4b3621"},
{source: "9: laboratory testing", target: "9: clinical trials", fill: "#4b3621"},
{source: "9: significant clinical", target: "10: commercialization", fill: "#a020f0"},
{source: "10: commercialization", target: "10: product candidates will", fill: "#a020f0"},
{source: "10: product candidates will", target: "10: necessary", fill: "#a020f0"},
{source: "10: necessary", target: "10: regulatory", fill: "#a020f0"},
{source: "10: regulatory", target: "10: sales marketing", fill: "#a020f0"},
{source: "10: sales marketing", target: "10: manufacturing", fill: "#a020f0"},
{source: "10: manufacturing", target: "10: capabilities either through internal hiring", fill: "#a020f0"},
{source: "10: capabilities either through internal hiring", target: "10: contractual relationships with others", fill: "#a020f0"},
{source: "10: commercialization", target: "16: product candidates", fill: "#ecebbd"},
{source: "16: product candidates", target: "16: based on", fill: "#ecebbd"},
{source: "16: based on", target: "16: technology", fill: "#ecebbd"},
{source: "16: technology", target: "16: could ultimately prove", fill: "#ecebbd"},
{source: "16: could ultimately prove", target: "16: ineffective", fill: "#ecebbd"},
{source: "16: product candidates", target: "18: clinical studies", fill: "#bb3385"},
{source: "18: clinical studies", target: "18: laboratory", fill: "#bb3385"},
{source: "18: laboratory", target: "18: candidates", fill: "#bb3385"},
{source: "18: clinical studies", target: "START_HERE", fill: "#bb3385"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Human illness</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_technology">Financial technology</a></td>
      <td>Financial technology (abbreviated fintech or FinTech) is the technology and innovation that aims to compete with traditional financial methods in the delivery of financial services. Artificial intelligence, Blockchain, Cloud computing, and big Data are regarded as the "ABCD" (four key areas) of FinTech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology_consulting">Information technology consulting</a></td>
      <td>In management, information technology consulting (also called IT consulting, computer consultancy, business and technology services, computing consultancy, technology consulting, and IT advisory) is a field of activity which focuses on advising organizations on how best to use information technology (IT) in achieving their business objectives.\nOnce a business owner defines the needs to take a business to the next level, a decision maker will define a scope, cost and a time frame of the project.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidate">Candidate</a></td>
      <td>A candidate, or nominee, is the prospective recipient of an award or honor, or a person seeking or being considered for some kind of position; for example:\n\nto be elected to an office — in this case a candidate selection procedure occurs.\nto receive membership in a  group"Nomination" is part of the process of selecting a candidate for either election to an office by a political party, or the bestowing of an honor or award.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Write-in_candidate">Write-in candidate</a></td>
      <td>A write-in candidate is a candidate whose name does not appear on the ballot but seeks election by asking voters to cast a vote for the candidate by physically writing in the person's name on the ballot. Depending on electoral law it may be possible to win an election by winning a sufficient number of such write-in votes, which count equally as if the person was formally listed on the ballot.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NEW RIVER PHARMACEUTICALS INC      ITEM 1A     RISK FACTORS       Risk Factors Related to Our Business             Except for the historical information contained in this annual report     on Form 10-K, this annual report on Form 10-K contains forward-looking     statements that <font color="blue">involve risks</font> and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>Our actual results may     <font color="blue">differ <font color="blue">materially</font> from</font> those discussed here</td>
    </tr>
    <tr>
      <td>Factors that could cause or     contribute to <font color="blue">differences</font> in our actual results include those discussed in     the  following section, as well as those discussed in Item 7 under the     section  entitled  “Management’s  Discussion and Analysis of Financial     Condition and Results of Operations” and elsewhere <font color="blue">throughout</font> this annual     report  on Form 10-K You should consider <font color="blue">carefully</font> the <font color="blue">following risk</font>     factors, together with all of the other information included in this annual     report on Form 10–K Each of these risk factors could <font color="blue">adversely</font> affect our     business, operating results and <font color="blue">financial condition</font>, as well as <font color="blue">adversely</font>     affect the value of an <font color="blue">investment</font> in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We have a history of operating losses and <font color="blue">may incur <font color="blue">additional</font></font> substantial     losses in 2006</td>
    </tr>
    <tr>
      <td>We may never achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">focused on product <font color="blue">development</font></font>, and through January 1, 2006 we     have not generated any <font color="blue">revenues utilizing</font> our Carrierwave <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">Since     </font>the end of 1997, we have incurred losses in each year of our <font color="blue">operations</font>, and     we <font color="blue">may continue</font> to incur operating losses in 2006</td>
    </tr>
    <tr>
      <td>These operating losses     have <font color="blue">adversely</font> affected and <font color="blue">may continue</font> to <font color="blue">adversely</font> affect our working     capital, total assets and <font color="blue">shareholders</font>’ equity</td>
    </tr>
    <tr>
      <td>The process of developing our products requires <font color="blue"><font color="blue">significant</font> clinical</font>,     <font color="blue">development</font>  and  <font color="blue"><font color="blue">laboratory</font> testing</font> and <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue">commercialization</font> of our <font color="blue"><font color="blue">product <font color="blue">candidates</font></font> will</font> require that we obtain     <font color="blue">necessary</font>  <font color="blue">regulatory</font>  approvals  and  establish  sales, marketing and     <font color="blue">manufacturing</font>  <font color="blue">capabilities</font>, either through internal hiring or through     <font color="blue">contractual <font color="blue">relationships</font> with others</font></td>
    </tr>
    <tr>
      <td>We may incur substantial losses in     2006 as a result of anticipated increases in our research and <font color="blue">development</font>     costs, including costs associated with conducting <font color="blue">preclinical testing</font> and     <font color="blue">clinical trials</font>, and <font color="blue">regulatory</font> compliance <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We have incurred     operating losses of <font color="blue">approximately</font> dlra31dtta8 million for the <font color="blue">fiscal year</font> ended     January 1, 2006, <font color="blue">approximately</font> dlra16dtta3 million for the <font color="blue">fiscal year</font> ended     January 2, 2005, and <font color="blue">approximately</font> dlra4dtta8 million for the <font color="blue">fiscal year</font> ended     <font color="blue">December </font>28, 2003 and at January 1, 2006, we had an <font color="blue">accumulated deficit</font> of     <font color="blue">approximately</font> dlra70 million</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">generate revenues</font> and achieve <font color="blue">profitability</font> will depend     <font color="blue">on numerous factors</font>, including success in:         •  developing and <font color="blue">testing <font color="blue">product <font color="blue">candidates</font></font></font>;         •  receiving <font color="blue">regulatory</font> approvals;         •  <font color="blue">commercializing</font> our products; and         •  <font color="blue">establishing</font> a favorable <font color="blue"><font color="blue">competitive</font> position</font></td>
    </tr>
    <tr>
      <td>Many of these factors <font color="blue">will depend on</font> <font color="blue">circumstances</font> beyond our control</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will ever have a product <font color="blue">approved by</font> the FDA,     that we will bring any product to market or, if we are successful in doing     so, that we <font color="blue">will ever <font color="blue">become profitable</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> are <font color="blue">based on</font> a <font color="blue">technology</font> that <font color="blue">could ultimately prove</font>     <font color="blue">in<font color="blue">effective</font></font> or unsafe</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> are created using our <font color="blue">proprietary</font> Carrierwave     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our test results to date are limited to <font color="blue">clinical studies</font> in     humans and pre<font color="blue">clinical studies</font> in animals <font color="blue">with respect</font> to NRP104 and NRP290     and <font color="blue">laboratory</font> tests and pre<font color="blue">clinical trials</font> in animals <font color="blue">with respect</font> to other     product  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We have not <font color="blue">fully characterized</font> the mechanism of     <font color="blue">absorption</font> of our CBDs</td>
    </tr>
    <tr>
      <td>Ultimately, our research and <font color="blue">preclinical findings</font>,     which  currently  indicate  that  our Carrierwave <font color="blue">technology</font> possesses     beneficial properties, may prove to be incorrect, in which case the product     <font color="blue">candidates</font>  created  using  our  Carrierwave <font color="blue">technology</font> may not differ     <font color="blue"><font color="blue">substantially</font> from competing drugs</font> and may in fact be inferior to them</td>
    </tr>
    <tr>
      <td>If     these products are                                         23       _________________________________________________________________    [72]Table of <font color="blue">Contents       </font><font color="blue"><font color="blue">substantially</font> identical</font> or inferior to <font color="blue">drugs already available</font>, the market     for our Carrierwave <font color="blue">drugs would</font> be reduced or eliminated</td>
    </tr>
    <tr>
      <td>Based on our preclinical and <font color="blue">clinical studies</font> to date, we believe our     lead <font color="blue">product <font color="blue">candidates</font></font> are safe and have no known side effects other than     those <font color="blue">associated <font color="blue">generally with</font> therapeutic amounts</font> of <font color="blue">amphetamine</font> and     opioids</td>
    </tr>
    <tr>
      <td>However, we may not be able to prove that our <font color="blue">product <font color="blue">candidates</font></font>     are safe</td>
    </tr>
    <tr>
      <td>No <font color="blue">assessment</font> of the efficacy, safety or side effects of a product     candidate can be considered complete until all <font color="blue">clinical trials</font> needed to     support a submission for <font color="blue">marketing approval</font> are complete</td>
    </tr>
    <tr>
      <td>Other than NRP104,     our <font color="blue"><font color="blue">product <font color="blue">candidates</font></font> will</font> require <font color="blue">additional</font> <font color="blue">laboratory</font>, animal and human     testing</td>
    </tr>
    <tr>
      <td>With respect to NRP104, we need to complete our <font color="blue">third clinical</font>     <font color="blue">abuse <font color="blue">liability</font> study</font></td>
    </tr>
    <tr>
      <td>Success in earlier clinical and pre<font color="blue">clinical trials</font>     does not mean that subsequent trials will confirm the earlier findings, or     that experience with use of a product in large-scale commercial <font color="blue">distribution</font>     will not identify <font color="blue"><font color="blue">additional</font> safety</font> or <font color="blue">efficacy issues</font></td>
    </tr>
    <tr>
      <td>If we find that any     of  our products is not safe, or if efficacy of the <font color="blue">products cannot</font> be     <font color="blue">consistently <font color="blue">demonstrate</font>d</font>, we may not be able to <font color="blue">commercialize</font> the product,     or may be required to <font color="blue">cease <font color="blue">distribution</font></font> of the product</td>
    </tr>
    <tr>
      <td>The safety of our     Carrierwave <font color="blue">formulations</font> may vary with each drug and the <font color="blue">ingredients used</font> in     each  formulation,  and  <font color="blue">therefore even</font> if safety and <font color="blue"><font color="blue">effective</font>ness</font> is     established for one of our CBDs, this would not <font color="blue">necessarily</font> be predictive of     the safety or <font color="blue"><font color="blue">effective</font>ness</font> of any of our other <font color="blue">product <font color="blue">candidates</font></font>, which     would need to be <font color="blue">separately established</font></td>
    </tr>
    <tr>
      <td>If we are unable to develop and <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font>     <font color="blue">successfully</font>, we may never achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We have not <font color="blue">commercialize</font>d any products or recognized any <font color="blue">revenue from</font>     <font color="blue"><font color="blue">product sales</font> utilizing</font> our Carrierwave <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>All of the compounds     produced using our Carrierwave <font color="blue">technology</font>, with the exception of NRP104 and     NRP290, are in <font color="blue">early stages</font> of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td><font color="blue">On January </font>26, 2006, <font color="blue">the FDA     </font>accepted  for  review  the NDA <font color="blue">application</font> for NRP104</td>
    </tr>
    <tr>
      <td>There can be no     assurance, however, that the FDA will approve that NDA or that, if <font color="blue">the FDA     </font>requires <font color="blue"><font color="blue">additional</font> data prior</font> to approval, that we will be able to generate     the  required data</td>
    </tr>
    <tr>
      <td>Other <font color="blue">than <font color="blue">with respect</font></font> to NRP104, we <font color="blue">must conduct</font>     <font color="blue"><font color="blue">significant</font> <font color="blue">additional</font> research</font> and <font color="blue">development</font> <font color="blue">activities</font> before we will be     able  to  apply  for <font color="blue">regulatory</font> approval to <font color="blue">commercialize</font> any products     utilizing our Carrierwave <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We must <font color="blue">successfully</font> complete adequate     and well-controlled studies designed to <font color="blue">demonstrate</font> the safety and efficacy     of the <font color="blue">product <font color="blue">candidates</font></font> and obtain <font color="blue">regulatory</font> approval before we are able     to <font color="blue">commercialize</font> these <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>There is no guarantee that we     will  receive  <font color="blue">regulatory</font>  <font color="blue">approval <font color="blue">with respect</font></font> to any of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Even if we succeed in developing and <font color="blue">commercializing</font> one or more     of our <font color="blue">product <font color="blue">candidates</font></font> utilizing our Carrierwave <font color="blue">technology</font>, we may never     <font color="blue">generate sufficient</font> or <font color="blue">sustainable revenue</font> to <font color="blue">enable us</font> to be profitable</td>
    </tr>
    <tr>
      <td>We <font color="blue">face intense <font color="blue">competition</font></font> in the <font color="blue">markets targeted by</font> our <font color="blue">lead product</font>     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue"><font color="blue">competitor</font>s</font> have <font color="blue">substantially</font> greater resources     than we do, and we expect that all of our <font color="blue">product <font color="blue">candidates</font></font> under     <font color="blue">development</font> will <font color="blue">face intense <font color="blue">competition</font></font> from existing or future drugs</td>
    </tr>
    <tr>
      <td>We have devoted substantial <font color="blue">research efforts</font> and capital to the     <font color="blue">development</font> of our Carrierwave <font color="blue">technology</font> and our lead <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We expect that all of our <font color="blue">product <font color="blue">candidates</font></font> under <font color="blue">development</font>, if approved,     will <font color="blue">face intense <font color="blue">competition</font></font> from existing and <font color="blue">future drugs marketed by</font>     large companies</td>
    </tr>
    <tr>
      <td>The markets for <font color="blue">amphetamine</font>s and other stimulants to treat ADHD and     opioids to treat pain are well developed and populated with established     drugs marketed by large <font color="blue">pharmaceutical</font>, bio<font color="blue">technology</font> and generic drug     companies</td>
    </tr>
    <tr>
      <td><font color="blue">Amphetamines </font>or other <font color="blue">stimulants <font color="blue">currently marketed</font></font> for <font color="blue">ADHD     </font>include  Ritalin  (Novartis AG), Concerta (McNeil Consumer &amp; Specialty     Pharmaceuticals), Dexedrine (GlaxoSmithKline PLC), Dextrostat (Shire),     Cylert (Abbott Laboratories, Inc</td>
    </tr>
    <tr>
      <td>) and Adderall (Shire)</td>
    </tr>
    <tr>
      <td>In addition, Eli     Lilly and Company markets a non-stimulant drug, Strattera, for ADHD Opioids     <font color="blue">currently marketed</font> for <font color="blue">acute pain</font> include Anexsia (Mallinckrodt Inc</td>
    </tr>
    <tr>
      <td>Opioids <font color="blue">currently marketed</font> for <font color="blue">chronic pain</font> include     OxyContin (Purdue Pharmaceuticals LP), Duragesic (Janssen Pharmaceutical     Products, LP), MSContin (Purdue Frederick Company) and Avinza (Ligand     Pharmaceuticals Inc</td>
    </tr>
    <tr>
      <td>Each of these companies has <font color="blue"><font color="blue">significant</font>ly</font> greater                                         24       _________________________________________________________________    [73]Table of <font color="blue">Contents       </font>financial and other <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>In addition, generic equivalent     versions of many of these <font color="blue">existing drug products</font> are available and these     products are therefore subject to substantial price <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>If we     obtain <font color="blue">regulatory</font> approval to market one or more of our <font color="blue">product <font color="blue">candidates</font></font>,     we will <font color="blue">compete with</font> these established brand and <font color="blue">generic drugs</font> and will need     to show that our drugs have safety or <font color="blue">efficacy <font color="blue">advantages</font></font> in order to take     market share and be successful</td>
    </tr>
    <tr>
      <td>Currently, and as a direct consequence of the <font color="blue">public debate</font> of the     social and <font color="blue">economic costs</font> of <font color="blue">illegal diversion</font> and abuse of, <font color="blue">addiction</font> to,     and <font color="blue">overdose from stimulants</font> and narcotics, several companies are pursuing     <font color="blue">formulations</font> that are less prone to abuse and are less toxic</td>
    </tr>
    <tr>
      <td><font color="blue">Companies     </font><font color="blue">specifically</font> engaged in developing <font color="blue">abuse resistant drugs</font> include Purdue     Pharma LP, Nastech Pharmaceutical Company Inc</td>
    </tr>
    <tr>
      <td>and <font color="blue">Pain Therapeutics Inc</font></td>
    </tr>
    <tr>
      <td>Other companies, including Johnson &amp; Johnson and Noven Pharmaceuticals,     Inc, are <font color="blue">investigating alternative delivery mechanisms</font> to control the     delivery and <font color="blue">availability</font> of <font color="blue">scheduled drugs</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">technologies</font> include     transdermal  skin  patches, metered dose inhalers and <font color="blue">extended release</font>     <font color="blue">subcutaneous injections</font> and implants</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">competitor</font>s</font> may:         •  <font color="blue">successfully</font> market products that <font color="blue">compete with</font> our products;         •  <font color="blue">successfully</font> identify drug <font color="blue">candidates</font> or develop <font color="blue">products earlier than</font>     we do; or         •  develop products that are more <font color="blue">effective</font>, have fewer side effects or     <font color="blue">cost less than</font> our products</td>
    </tr>
    <tr>
      <td>Additionally, if a <font color="blue">competitor</font> receives FDA approval before we do for a     drug that is similar to one of our <font color="blue">product <font color="blue">candidates</font></font>, FDA approval for our     <font color="blue"><font color="blue">product candidate</font> may</font> be precluded or <font color="blue">delayed due</font> to periods of non-patent     <font color="blue">exclusivity</font> and/or the <font color="blue">listing with</font> the FDA by the <font color="blue">competitor</font> of patents     covering its newly-approved drug product</td>
    </tr>
    <tr>
      <td>Periods of non-patent <font color="blue">exclusivity</font>     for new versions of existing drugs such as our current <font color="blue">product <font color="blue">candidates</font></font>     can extend up to three and one-half years</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">competitive</font> factors could</font> require us to conduct substantial new     research and <font color="blue">development</font> <font color="blue">activities</font> to establish new product targets, which     would be costly and time consuming</td>
    </tr>
    <tr>
      <td>These <font color="blue">activities</font> would <font color="blue">adversely</font> affect     our ability to <font color="blue">commercialize</font> products and achieve revenue and profits</td>
    </tr>
    <tr>
      <td>If we fail to protect our <font color="blue"><font color="blue">intellectual</font> <font color="blue">property rights</font></font>, our ability to     pursue the <font color="blue">development</font> of our <font color="blue">technologies</font> and <font color="blue">products would</font> be <font color="blue">negatively</font>     affected</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part on our ability to obtain patents and     maintain <font color="blue">adequate protection</font> of our <font color="blue">technologies</font> and products</td>
    </tr>
    <tr>
      <td>If we do not     <font color="blue">adequately protect</font> our <font color="blue">intellectual</font> property, <font color="blue"><font color="blue">competitor</font>s</font> may be able to use     our <font color="blue">technologies</font> to produce and <font color="blue">market drugs</font> in direct <font color="blue">competition</font> with us     and erode our <font color="blue"><font color="blue">competitive</font> advantage</font></td>
    </tr>
    <tr>
      <td>Some foreign countries lack rules and     methods  for defending <font color="blue"><font color="blue">intellectual</font> <font color="blue">property rights</font></font> and do not protect     <font color="blue">proprietary</font> rights to the <font color="blue">same extent as</font> the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Many companies     have had <font color="blue"><font color="blue">difficult</font>y protecting</font> their <font color="blue">proprietary</font> rights in these foreign     countries</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">prevent misappropriation</font> of our <font color="blue">proprietary</font>     rights</td>
    </tr>
    <tr>
      <td>Patent positions can be uncertain and <font color="blue">involve complex legal</font> and     factual questions</td>
    </tr>
    <tr>
      <td>We can protect our <font color="blue">proprietary</font> rights from unauthorized     <font color="blue">use <font color="blue">by <font color="blue">third parties</font></font> only</font> to the extent that our <font color="blue">proprietary</font> <font color="blue">technologies</font>     are <font color="blue">covered by valid</font> and <font color="blue">enforceable patents</font> or are <font color="blue">effective</font>ly maintained     <font color="blue">as <font color="blue">trade secrets</font></font></td>
    </tr>
    <tr>
      <td>To date, we hold one issued US patent relating to our     core Carrierwave <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In addition to the <font color="blue">core patent</font>, we have two     issued US patents for an earlier developed delivery <font color="blue">technology</font> related to     Carrierwave, and one directed to <font color="blue">iodothyronine</font> compounds</td>
    </tr>
    <tr>
      <td>We have applied     for <font color="blue">additional</font> patents relating to our <font color="blue">technologies</font> and our products and     plan  to  file  <font color="blue">additional</font>  patent <font color="blue">application</font>s in the future</td>
    </tr>
    <tr>
      <td>We have     US patent <font color="blue">application</font>s pending covering each of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Additionally,  we  have <font color="blue">Patent Cooperation Treaty </font><font color="blue">application</font>s pending     <font color="blue">covering abuse resistant aspects</font> of our <font color="blue">technology</font>, as well as, national     stage <font color="blue">application</font>s pending in up to 18 countries depending on the specific     <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>We also have national stage <font color="blue">application</font>s covering our     core <font color="blue">technology</font> platform in Europe, Japan, China, South Korea, Canada,     Australia, India and Israel</td>
    </tr>
    <tr>
      <td>Others <font color="blue">may challenge</font> our patents, or our patent <font color="blue">application</font>s may not     result in <font color="blue">issued patents</font></td>
    </tr>
    <tr>
      <td>Moreover, any patents issued to us may not provide     us with <font color="blue">meaningful</font> protection, or others <font color="blue">may challenge</font>, <font color="blue">circumvent</font>                                         25       _________________________________________________________________    [74]Table of <font color="blue">Contents       </font>or narrow our patents</td>
    </tr>
    <tr>
      <td>Third <font color="blue"><font color="blue">parties may</font> also in<font color="blue">dependent</font>ly</font> develop products     similar to our products, duplicate our <font color="blue">unpatented products</font> or <font color="blue">design around</font>     any <font color="blue">patents on products</font> we develop</td>
    </tr>
    <tr>
      <td>Additionally, extensive time is required     for <font color="blue">development</font>, testing and <font color="blue">regulatory</font> review of a <font color="blue">potential product</font></td>
    </tr>
    <tr>
      <td><font color="blue">While     </font><font color="blue">extensions</font> of patent term due to <font color="blue">regulatory</font> delays may be available, it is     possible that, before any of our <font color="blue">product <font color="blue">candidates</font></font> can be <font color="blue">commercialize</font>d,     any related patent, even with an extension, may expire or remain in force     for only a short period following <font color="blue">commercialization</font>, thereby reducing any     <font color="blue">advantages</font> of the patent</td>
    </tr>
    <tr>
      <td>In addition to patents, we rely on a <font color="blue">combination</font> of <font color="blue">trade secrets</font>,     <font color="blue">confidential</font>ity,  <font color="blue">non<font color="blue">disclosure</font></font>  and other <font color="blue">contractual provisions</font>, and     <font color="blue">security measures</font> to protect our <font color="blue">confidential</font> and <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>These  measures  may not <font color="blue">adequately protect</font> our <font color="blue">trade secrets</font> or other     <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>If they do not <font color="blue">adequately protect</font> our rights, third     parties  could  use  our <font color="blue">technology</font>, and we <font color="blue">could lose</font> any <font color="blue">competitive</font>     advantage we may have</td>
    </tr>
    <tr>
      <td>In addition, others may in<font color="blue">dependent</font>ly develop similar     <font color="blue">proprietary</font> information or <font color="blue">techniques</font> or <font color="blue">otherwise gain access</font> to our trade     secrets, which could impair any <font color="blue"><font color="blue">competitive</font> advantage</font> we may have</td>
    </tr>
    <tr>
      <td>We have not <font color="blue">commissioned</font> an extensive <font color="blue">investigation concerning</font> our freedom     to practice or the validity or <font color="blue">enforceability</font> of our Carrierwave <font color="blue">technology</font>     or <font color="blue">product <font color="blue">candidates</font></font>, and we may be held to infringe the <font color="blue">intellectual</font>     <font color="blue">property rights</font> of others</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">freely practice</font> our <font color="blue">product <font color="blue">candidates</font></font> is <font color="blue">dependent</font>     upon the duration and scope of patents held <font color="blue">by <font color="blue">third parties</font></font></td>
    </tr>
    <tr>
      <td>Our patent,     prior art and <font color="blue"><font color="blue">infringement</font> investigations</font> have <font color="blue">been conducted primarily by</font>     us</td>
    </tr>
    <tr>
      <td>Although we have <font color="blue">consulted with</font> our <font color="blue">patent counsel</font> in <font color="blue"><font color="blue">connection</font> with</font>     our  <font color="blue">intellectual</font>  <font color="blue">property investigations</font>, our <font color="blue">patent counsel</font> has not     undertaken  an extensive in<font color="blue">dependent</font> analysis to determine whether our     Carrierwave  <font color="blue">technology</font> or <font color="blue">product <font color="blue">candidates</font></font> infringe upon any issued     patents or whether our <font color="blue">issued patents</font> or patent <font color="blue">application</font>s relating to our     Carrierwave <font color="blue">technology</font> could be invalidated or rendered unenforceable for     any reason or could be subject to <font color="blue"><font color="blue">interference</font> <font color="blue">proceedings</font></font></td>
    </tr>
    <tr>
      <td>There may be patents or patent <font color="blue">application</font>s of which we are unaware,     and <font color="blue">avoiding patent <font color="blue">infringement</font> may</font> be <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may inadvertently</font>     infringe third-party patents</td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">patents may impair</font> or block our     ability to conduct our business</td>
    </tr>
    <tr>
      <td>There are <font color="blue">no unresolved communications</font>,     allegations, <font color="blue">complaints</font> or threats of <font color="blue">litigation</font> related to the <font color="blue">possibility</font>     that we <font color="blue">might infringe patents</font> held by others</td>
    </tr>
    <tr>
      <td>Claims may be asserted <font color="blue">against us</font> that our products or <font color="blue">technology</font>     <font color="blue">infringes patents</font> or other <font color="blue">intellectual</font> property owned by others</td>
    </tr>
    <tr>
      <td>We may be     exposed to future <font color="blue">litigation</font> <font color="blue">by <font color="blue">third parties</font></font> <font color="blue">based on</font> claims that our     products or <font color="blue"><font color="blue">activities</font> infringe</font> the <font color="blue"><font color="blue">intellectual</font> <font color="blue">property rights</font></font> of others</td>
    </tr>
    <tr>
      <td>In the event of <font color="blue">litigation</font>, any claims may not be resolved in our favor</td>
    </tr>
    <tr>
      <td>Any     <font color="blue">litigation</font>  or  claims <font color="blue">against us</font>, whether or not valid, may result in     substantial costs and may result in an award of damages, lost profits,     <font color="blue">attorneys fees</font>, and tripling of those damages in the event that a court     finds an <font color="blue">infringement</font> to have <font color="blue">been willful</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">lawsuit could also</font> place a     <font color="blue">significant</font> strain on our financial resources, divert the attention of     <font color="blue">management</font> and harm our reputation</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">intellectual</font> property     <font color="blue">litigation</font> or claims <font color="blue">could force us</font> to do one or more of the following:         •  cease making, using, selling, offering to sell or importing any     products that infringe a third party’s <font color="blue">intellectual</font> property through an     injunction;         •  obtain a license or an <font color="blue">assignment from</font> the holder of the infringed     <font color="blue">intellectual</font> property right, <font color="blue">which license</font> or <font color="blue">assignment may</font> be costly or     may not be <font color="blue">available on reasonable terms</font>, if at all; or         •  redesign our products, which would be costly and time-consuming and may     not be possible</td>
    </tr>
    <tr>
      <td>We may be involved in lawsuits to protect or enforce our patents, which     could be expensive and time-consuming</td>
    </tr>
    <tr>
      <td>Our <font color="blue">intellectual</font> property includes four US patents, two foreign     patents and 102 pending US, <font color="blue">Patent Cooperation Treaty </font>or national stage     <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>We have <font color="blue">licensed aspects</font> of our Carrierwave <font color="blue">technology</font> with     respect to NRP104 pursuant to our <font color="blue"><font color="blue">collaboration</font> <font color="blue">agreement</font> with</font> Shire</td>
    </tr>
    <tr>
      <td>We     have 54 <font color="blue">application</font>s covering anti-abuse aspects of NRP104, NRP290 and     NRP369 <font color="blue">generally with</font> other <font color="blue">commonly abused</font>                                         26       _________________________________________________________________    [75]Table of <font color="blue">Contents       </font>substances</td>
    </tr>
    <tr>
      <td>Of these, NRP104 is the focus of 25 <font color="blue">application</font>s, NRP290 is the     focus of two <font color="blue">application</font>s, NRP369 is the focus of three <font color="blue">application</font>s, and     NRP409 is the focus of one <font color="blue">application</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may infringe our patents, and we may file <font color="blue">infringement</font>     claims to counter <font color="blue">infringement</font> or <font color="blue">unauthorized use</font></td>
    </tr>
    <tr>
      <td>This can be expensive,     <font color="blue">particularly</font> for a company of our size, and time-consuming</td>
    </tr>
    <tr>
      <td>In addition, in     an <font color="blue">infringement</font> proceeding, a <font color="blue">court may decide</font> that a patent of ours is not     valid or is unenforceable, or may refuse to stop the other <font color="blue">party from using</font>     the <font color="blue">technology</font> at issue on the grounds that our patents do not cover its     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>An  adverse  <font color="blue">de<font color="blue">termination</font></font>  of  any <font color="blue">litigation</font> or defense     <font color="blue">proceedings</font>  could  put  one  or  more of our <font color="blue">patents at risk</font> of being     invalidated or <font color="blue">interpreted narrowly</font></td>
    </tr>
    <tr>
      <td>There  are  <font color="blue">no unresolved communications</font>, allegations,     <font color="blue">complaints</font> or threats of <font color="blue">litigation</font> related to the <font color="blue">possibility</font> that our     patents are invalid or unenforceable</td>
    </tr>
    <tr>
      <td>Any <font color="blue">litigation</font> or claims <font color="blue">against us</font>,     whether or not merited, may result in substantial costs, place a <font color="blue">significant</font>     strain on our financial resources, divert the attention of <font color="blue">management</font> and     harm our reputation</td>
    </tr>
    <tr>
      <td>An <font color="blue">adverse decision</font> in a <font color="blue">litigation</font> could result in     in<font color="blue">adequate protection</font> for our <font color="blue">product <font color="blue">candidates</font></font> and/or reduce the value of     any <font color="blue">license <font color="blue">agreement</font>s</font> we have <font color="blue">with <font color="blue">third parties</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Interference </font><font color="blue">proceedings</font> brought before the US Patent and Trademark     Office may be <font color="blue">necessary</font> to determine priority of <font color="blue">invention <font color="blue">with respect</font></font> to     our patents or patent <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>During an <font color="blue">interference</font> proceeding, it     may be determined that we do not have priority of invention for one or more     aspects  in our patents or patent <font color="blue">application</font>s and could result in the     <font color="blue">invalidation</font> in part or whole of a patent or <font color="blue">could put</font> a patent <font color="blue">application</font>     at risk of not issuing</td>
    </tr>
    <tr>
      <td>Even if successful, an <font color="blue">interference</font> may result in     substantial costs and <font color="blue">distraction</font> to our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Furthermore, because of the substantial amount of <font color="blue">discovery</font> required     in  <font color="blue">connection</font>  with  <font color="blue">intellectual</font> property <font color="blue">litigation</font> or <font color="blue">interference</font>     <font color="blue">proceedings</font>, there is a risk that some of our <font color="blue">confidential</font> information could     be  <font color="blue">compromised</font>  by  <font color="blue">disclosure</font></td>
    </tr>
    <tr>
      <td>In  addition,  there could be public     <font color="blue">announcements</font>  of  the  results  of hearings, motions or other interim     <font color="blue">proceedings</font> or <font color="blue">development</font>s</td>
    </tr>
    <tr>
      <td>If investors perceive these results to be     negative, the price of our <font color="blue">common stock</font> could be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>If <font color="blue">preclinical testing</font> or <font color="blue">clinical trials</font> for our <font color="blue">product <font color="blue">candidates</font></font> are     <font color="blue">unsuccessful</font> or delayed, we will be unable to meet our anticipated     <font color="blue">development</font> and <font color="blue">commercialization</font> timelines</td>
    </tr>
    <tr>
      <td>Other than NRP104, our <font color="blue">potential drug products</font> require preclinical     testing  and  clinical  trials  prior  to submission of any <font color="blue">regulatory</font>     <font color="blue">application</font> for <font color="blue"><font color="blue">commercial sale</font>s</font></td>
    </tr>
    <tr>
      <td>With respect to NRP104, our <font color="blue">third clinical</font>     <font color="blue">abuse <font color="blue">liability</font> study</font> is ongoing, as is our continuing long-term safety     study</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">clinical study <font color="blue"><font color="blue">requirement</font>s</font> could</font> be <font color="blue"><font color="blue">imposed on us</font> either</font>     prior  to  approval  or as post-approval <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>We have limited     experience conducting <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">currently employ two clinical</font>     <font color="blue">trial managers</font></td>
    </tr>
    <tr>
      <td>We rely and expect to continue to <font color="blue">rely on <font color="blue">third parties</font></font>,     including  <font color="blue">clinical <font color="blue">research organizations</font></font> and <font color="blue">outside consultants</font>, to     conduct, supervise or monitor some or all aspects of <font color="blue">preclinical testing</font> or     <font color="blue">clinical trials</font> involving our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">less <font color="blue">control over</font></font>     the timing and other aspects of these <font color="blue">preclinical testing</font> or <font color="blue">clinical trials</font>     than if we performed the monitoring and <font color="blue">supervision entirely on</font> our own</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> not perform their <font color="blue">responsibilities</font> for our preclinical     testing or <font color="blue">clinical trials</font> on our anticipated schedule or, for clinical     trials, consistent with a <font color="blue">clinical trial protocol</font></td>
    </tr>
    <tr>
      <td>Delays in preclinical and     clinical testing could <font color="blue"><font color="blue">significant</font>ly</font> increase our product <font color="blue">development</font> costs     and delay product <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>In addition, many of the factors that     may cause, or lead to, a delay in the <font color="blue">clinical trials</font> may also ultimately     lead to denial of <font color="blue">regulatory</font> approval of a <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>The commencement of <font color="blue">clinical trials</font> can be delayed for a variety of     reasons, including delays in:         •  <font color="blue">demonstrating sufficient safety</font> and efficacy to obtain <font color="blue">regulatory</font>     approval to commence a clinical trial;          •  <font color="blue">reaching <font color="blue">agreement</font> on</font> acceptable <font color="blue">terms with prospective contract</font>     <font color="blue">research organizations</font> and <font color="blue">trial sites</font>;         •  <font color="blue">manufacturing</font> <font color="blue">sufficient quantities</font> of a <font color="blue">product candidate</font>; and         •  obtaining <font color="blue">institutional review board approval</font> to conduct a clinical     trial at a <font color="blue">prospective site</font></td>
    </tr>
    <tr>
      <td>27       _________________________________________________________________    [76]Table of <font color="blue">Contents       </font>      Once a clinical trial has begun, it may be delayed, suspended or     terminated by us <font color="blue">or the FDA </font>or other <font color="blue">regulatory</font> authorities due to a number     of factors, including:         •  <font color="blue">ongoing discussions with</font> the FDA or other <font color="blue">regulatory</font> authorities     regarding the scope or design of our <font color="blue">clinical trials</font>;          •  failure to conduct <font color="blue">clinical trials</font> in <font color="blue">accordance with</font> <font color="blue">regulatory</font>     <font color="blue"><font color="blue">requirement</font>s</font>;         •  lower than anticipated <font color="blue">recruitment</font> or <font color="blue">retention rate</font> of patients in     <font color="blue">clinical trials</font>;         •  inspection of the clinical trial <font color="blue">operations</font> or <font color="blue">trial sites</font> by <font color="blue">the FDA     </font>or other <font color="blue">regulatory</font> authorities resulting in the imposition of a clinical     hold;         •  lack of <font color="blue">adequate funding</font> to continue <font color="blue">clinical trials</font>; or         •  negative results of <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">clinical trials</font> are <font color="blue">unsuccessful</font>, and we are not able to obtain     <font color="blue">regulatory</font> approvals for our <font color="blue">product <font color="blue">candidates</font></font> under <font color="blue">development</font>, we will     not be able to <font color="blue">commercialize</font> these products, and <font color="blue">therefore may</font> not be able     to <font color="blue">generate sufficient</font> revenues to support our business</td>
    </tr>
    <tr>
      <td>We have received an <font color="blue"><font color="blue">observation</font> from</font> the FDA noting that we did not submit     an IND before conducting certain <font color="blue">clinical studies</font> in 2001</td>
    </tr>
    <tr>
      <td>FDA has the authority to inspect a company’s drug <font color="blue">manufacturing</font> and     <font color="blue">testing processes</font> and to take enforcement actions, with varying degrees of     severity, in the event that it determines that violations of the Federal     Food, Drug and Cosmetic Act and FDA <font color="blue">regulations</font> have occurred</td>
    </tr>
    <tr>
      <td>In late <font color="blue">April     </font>2004,  <font color="blue">representatives</font> of the FDA inspected our <font color="blue">laboratory</font> facility in     Blacksburg, Virginia</td>
    </tr>
    <tr>
      <td>In <font color="blue"><font color="blue">connection</font> with</font> this inspection, the FDA issued an     <font color="blue"><font color="blue">observation</font> on</font> Form FDA-483 relating to our conduct of <font color="blue">pharmacokinetic</font>     <font color="blue">studies on thyroid compounds</font> in humans in 2001</td>
    </tr>
    <tr>
      <td>The <font color="blue">observation</font> noted that     we did not submit an IND <font color="blue">application</font> before conducting these studies</td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font>an <font color="blue"><font color="blue">observation</font> on</font> Form FDA-483 does not <font color="blue">constitute</font> a <font color="blue">finding by</font> FDA that a     violation has occurred</td>
    </tr>
    <tr>
      <td>We have responded to this <font color="blue">observation</font>, explaining     our basis for believing in 2001 that these studies were <font color="blue">exempt from</font> FDA     <font color="blue">regulations</font> requiring submission of an IND In <font color="blue">subsequent correspondence</font>     with the FDA, the FDA has <font color="blue">informed us</font> that it believes those <font color="blue">studies should</font>     have <font color="blue">been conducted under</font> an IND, and we have agreed to assure that future     studies of this type are conducted under IND <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>We do not believe     that any enforcement action <font color="blue">against us</font> by the FDA <font color="blue">based on</font> this <font color="blue">observation</font>     would  be  warranted or that, if pursued, any <font color="blue">such action would</font> have a     material effect on us or our business</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>does not accept our <font color="blue">filing under</font> Section 505(b)(1) and we are     unable to file for <font color="blue">approval under</font> Section 505(b)(2) of the Federal Food,     Drug and Cosmetic Act or if we are required to generate <font color="blue">additional</font> data     related to safety and efficacy in order to obtain <font color="blue">approval under</font>     Section 505(b)(1) or 505(b)(2), we may be unable to meet our anticipated     <font color="blue">development</font> and <font color="blue">commercialization</font> timelines</td>
    </tr>
    <tr>
      <td>Our current plans for filing NDAs for our <font color="blue">product <font color="blue">candidates</font></font> include     efforts to minimize the data we will be required to generate in order to     obtain <font color="blue">marketing approval</font> for our <font color="blue">product <font color="blue">candidates</font></font> and therefore possibly     obtain a shortened review period for the <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>The FDA could     change its <font color="blue">de<font color="blue">termination</font></font> on this issue, however, and require that we either     generate <font color="blue">additional</font> data to support an <font color="blue">approval under</font> Section 505(b)(1) or     submit or convert an <font color="blue">application</font> to a Section 505(b)(2) <font color="blue">application</font> so that     we can rely on data generated <font color="blue">by <font color="blue">third parties</font></font>, to which we do not have a     right  of reference</td>
    </tr>
    <tr>
      <td>If we are required to <font color="blue">rely on data generated with</font>     products already <font color="blue">approved by</font> the FDA and covered by third-party patents we     would be required to certify that we do not infringe the listed patents for     those products or that such patents are invalid or unenforceable</td>
    </tr>
    <tr>
      <td>As a     result of such a <font color="blue">certification</font>, the third party would have 45 days from     <font color="blue">notification</font>  of  our  <font color="blue">certification</font>  to initiate an action for patent     <font color="blue">infringement</font> <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>In the event that an action is brought in response     to such a <font color="blue">certification</font>, the approval of our NDA could be subject to a stay     of up to 30 months or more while we <font color="blue">defend against such</font> a suit</td>
    </tr>
    <tr>
      <td>28       _________________________________________________________________    [77]Table of <font color="blue">Contents       </font>Approval of our <font color="blue">product <font color="blue">candidates</font></font> may therefore be delayed until patent     <font color="blue">exclusivity</font> expires or until we <font color="blue">successfully</font> challenge the <font color="blue">applicability</font> of     those patents to our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Alternatively, we may elect to     <font color="blue">generate sufficient</font> <font color="blue">additional</font> clinical data of our own so that we can     maintain our <font color="blue">application</font> under Section 505(b)(1)</td>
    </tr>
    <tr>
      <td>Even if no <font color="blue">exclusivity</font> periods apply to our <font color="blue">application</font>s, the FDA has     <font color="blue">broad discretion</font> to require us to generate <font color="blue">additional</font> data on the safety and     efficacy of our <font color="blue">product <font color="blue">candidates</font></font> to supplement third-party data on which     we may be permitted to rely</td>
    </tr>
    <tr>
      <td>In <font color="blue">either event</font>, we could be required, before     obtaining <font color="blue">marketing approval</font> for any of our <font color="blue">product <font color="blue">candidates</font></font>, to conduct     substantial  new  research  and <font color="blue">development</font> <font color="blue">activities</font> beyond those we     currently  plan  to  engage in order to obtain approval of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">additional</font> new research and <font color="blue">development</font> <font color="blue">activities</font> would be     costly and time consuming</td>
    </tr>
    <tr>
      <td>If we are required to generate <font color="blue">additional</font> data to     <font color="blue">support approval</font>, we may be unable to meet our anticipated <font color="blue">development</font> and     <font color="blue">commercialization</font> timelines, may be unable to generate the <font color="blue">additional</font> data     at a <font color="blue">reasonable cost</font>, or at all, and may be unable to obtain marketing     approval of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>requires that NRP104 be <font color="blue">scheduled by</font> the DEA before the product     is <font color="blue">commercially sold</font>, we will be unable to <font color="blue">begin <font color="blue">commercial sale</font></font> of that     <font color="blue">product until</font> the DEA completes scheduling <font color="blue">proceedings</font>, and if NRP104 is     <font color="blue">scheduled by</font> the <font color="blue">DEA in <font color="blue">Schedule II </font></font>under the Controlled Substances Act     (CSA), the potential market for the drug may be <font color="blue"><font color="blue">significant</font>ly</font> reduced</td>
    </tr>
    <tr>
      <td>The DEA has indicated that NRP104 is not a <font color="blue">scheduled drug at</font> the     present time</td>
    </tr>
    <tr>
      <td>Based on data generated in our studies of the potential for     abuse,  however,  and on the fact that the drug is designed to deliver     quantities  of <font color="blue">amphetamine</font>, the <font color="blue">FDA and the DEA </font>may, pursuant to their     statutory <font color="blue">responsibilities</font> under the CSA, conclude that the <font color="blue">drug should</font> be     scheduled in one of the CSA <font color="blue">schedules at</font> the time it is <font color="blue">first approved</font> for     <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>The process for scheduling a drug under these <font color="blue">circumstances</font>     involves the <font color="blue">forwarding by</font> the <font color="blue">FDA to the DEA </font>of its medical and scientific     findings,  and  its  <font color="blue">recommendation</font>  that the drug be scheduled on the     <font color="blue">appropriate</font> schedule level</td>
    </tr>
    <tr>
      <td>The DEA <font color="blue">then publishes</font> a notice in the Federal     Register of a proposal to place the drug in an <font color="blue">appropriate</font> CSA schedule</td>
    </tr>
    <tr>
      <td><font color="blue">Interested  </font>persons are then afforded an <font color="blue">opportunity</font> to <font color="blue">comment on</font> the     proposal and to request a hearing</td>
    </tr>
    <tr>
      <td>After <font color="blue">consideration</font> of the comments     received, and <font color="blue">potentially</font> the holding of a <font color="blue">formal administrative</font> hearing,     the DEA <font color="blue">then publishes</font> a <font color="blue">regulation placing</font> the drug in an <font color="blue">appropriate</font> CSA     schedule</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>is unwilling to permit the sale of the drug until it is     placed in an <font color="blue">appropriate</font> CSA schedule, it may not grant NDA <font color="blue">approval until</font>     <font color="blue">completion</font> of scheduling <font color="blue">proceedings</font> by the DEA We intend to <font color="blue">seek timely</font>     <font color="blue">conclusion</font> of any <font color="blue">consideration</font> of the CSA scheduling of NRP104 so that     these <font color="blue">consideration</font>s do not result in any delay in our ability to market the     drug</td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">opportunity</font> for <font color="blue">public participation</font> in the process,     however, we <font color="blue"><font color="blue">cannot predict</font> how long</font> the <font color="blue">FDA and the DEA </font>may take to conclude     any <font color="blue">scheduling actions <font color="blue">with respect</font></font> to the drug that they may believe are     warranted</td>
    </tr>
    <tr>
      <td>The drug products with which our <font color="blue">lead product</font> candidate NRP104 is     expected to compete are <font color="blue">amphetamine</font> products currently classified by the DEA     under the CSA on Schedule II, the most <font color="blue">restrictive</font> schedule applicable to     drug products marketed for legitimate medical use</td>
    </tr>
    <tr>
      <td>The DEA has concluded     that, <font color="blue">based on</font> its <font color="blue">chemical structure</font>, NRP104 is not a scheduled substance     at the present time</td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercialization</font> strategy for this <font color="blue">product depends</font>     in large part on our ability to obtain approval to market the <font color="blue">drug either as</font>     an <font color="blue">unscheduled drug</font> or as a <font color="blue">drug classified by</font> the DEA in a less <font color="blue">restrictive</font>     <font color="blue">schedule than</font> <font color="blue">Schedule II </font>A <font color="blue">decision as</font> to whether and how NRP104 should be     <font color="blue">scheduled at</font> the time it is approved for <font color="blue">commercial sale</font> will be made by the     DEA <font color="blue">based on</font> the medical and scientific <font color="blue">de<font color="blue">termination</font></font>s of the FDA which, in     turn, will be based in large part on data we generate regarding the relative     potential for abuse of the <font color="blue">drug compared</font> to existing <font color="blue">Schedule II </font>drugs</td>
    </tr>
    <tr>
      <td>If     the <font color="blue">de<font color="blue">termination</font></font> is made that the <font color="blue">drug should</font> be controlled in Schedule II,     the potential market for our drug may be <font color="blue"><font color="blue">significant</font>ly</font> reduced, which may     have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>Furthermore, because <font color="blue">amphetamine</font> is a     <font color="blue">Schedule II </font>substance, the amount of it that we can obtain for clinical     trials and <font color="blue">commercialization</font> of NRP104 is limited by the DEA and our quota     may not be sufficient to complete <font color="blue">clinical trials</font> or meet commercial demand</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the outcome of the studies of the potential for abuse of     our drug or of the <font color="blue">consideration</font> by the <font color="blue">FDA and the DEA </font>of the results of     those studies</td>
    </tr>
    <tr>
      <td>29       _________________________________________________________________    [78]Table of <font color="blue">Contents       </font>We have engaged in extensive financial and <font color="blue">operational <font color="blue">transactions</font> with</font>     Randal J Kirk, our Chairman, President and Chief Executive Officer, and his     <font color="blue">affiliates</font></td>
    </tr>
    <tr>
      <td>Our company was <font color="blue">formed by</font>, and has <font color="blue">historically been controlled</font> and     managed and, prior to the <font color="blue">initial public offering</font> of our <font color="blue">common stock</font>,     <font color="blue">principally funded by</font>, Randal J Kirk, our Chairman, President and Chief     Executive Officer, and <font color="blue">affiliates</font> of Mr</td>
    </tr>
    <tr>
      <td>As a result, we have engaged     in a variety of financial and <font color="blue">operational <font color="blue">transactions</font> with</font> Mr</td>
    </tr>
    <tr>
      <td>Kirk and     these <font color="blue">affiliates</font></td>
    </tr>
    <tr>
      <td>While we believe that each of these <font color="blue">transactions</font> was on     terms  no  less favorable to <font color="blue">us than terms</font> we could have obtained from     un<font color="blue">affiliated</font> <font color="blue">third parties</font>, none of these <font color="blue">transactions</font> was <font color="blue">negotiated on</font> an     arm’s length basis</td>
    </tr>
    <tr>
      <td>Accordingly, their terms may not be as favorable to us     as if we had <font color="blue">negotiated them with un<font color="blue">affiliated</font> <font color="blue">third parties</font></font></td>
    </tr>
    <tr>
      <td>It is our     intention to ensure that all future <font color="blue">transactions</font>, if any, <font color="blue">between us</font> and our     officers,  <font color="blue">directors</font>, principal <font color="blue">shareholders</font> and their <font color="blue">affiliates</font>, are     approved  by  the <font color="blue">audit committee</font> or a majority of the in<font color="blue">dependent</font> and     <font color="blue">disinterested members</font> of the board of <font color="blue">directors</font>, and are <font color="blue">on <font color="blue">terms no less</font></font>     favorable to us than those that we could obtain <font color="blue">from un<font color="blue">affiliated</font> third</font>     parties</td>
    </tr>
    <tr>
      <td><font color="blue">As of January </font>1, 2006 <font color="blue">Randal J Kirk </font>controlled <font color="blue">approximately</font> 56dtta8prca of our     <font color="blue">common stock</font> and is able to control or <font color="blue"><font color="blue">significant</font>ly</font> influence corporate     actions, which may result in Mr</td>
    </tr>
    <tr>
      <td>Kirk taking actions that advance his     interests to the detriment of our other <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of January </font>1, 2006 Randal J Kirk, Chairman, President and Chief     Executive  Officer,  and  <font color="blue">shareholders</font>  <font color="blue">affiliated</font> with him controlled     <font color="blue">approximately</font> 56dtta8prca of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Kirk is able to control or     <font color="blue"><font color="blue">significant</font>ly</font> influence all matters requiring approval by our <font color="blue">shareholders</font>,     including the election of <font color="blue">directors</font> and the approval of mergers or other     business <font color="blue">combination</font> <font color="blue">transactions</font></td>
    </tr>
    <tr>
      <td>Kirk may not always     <font color="blue">coincide with</font> the interests of other <font color="blue">shareholders</font>, and he may take actions     that advance his interests to the detriment of our other <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">Third Security</font>, LLC, to provide us with certain services</td>
    </tr>
    <tr>
      <td>If     <font color="blue">Third Security</font>, LLC ceases to provide these services and we are unable to     establish and maintain the <font color="blue">necessary</font> <font color="blue">infrastructure</font> to be self-sufficient,     our business will be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">Third Security</font>, LLC to provide support for tax, legal,     information <font color="blue">technology</font>, and market research functions as well as provide the     <font color="blue">miscellaneous</font> services that we may need from time to time until the earlier     of  August 9,  2006  or our <font color="blue">termination</font> of the <font color="blue">administrative services</font>     <font color="blue">agreement</font> we have with <font color="blue">Third Security</font></td>
    </tr>
    <tr>
      <td>Currently, we expect to renew this     <font color="blue">agreement</font> under similar <font color="blue">terms upon</font> its expiration</td>
    </tr>
    <tr>
      <td>If <font color="blue">Third Security</font> will     not agree to renew the <font color="blue">agreement</font> and ceases to provide these services and we     are  unable to add the <font color="blue">necessary</font> personnel and establish the <font color="blue">necessary</font>     <font color="blue">infrastructure</font> to support our <font color="blue">operations</font> as a result, our business will be     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td><font color="blue">Third Security</font> is owned by Randal J Kirk, our Chairman,     President and Chief Executive Officer, who, with <font color="blue">shareholders</font> <font color="blue">affiliated</font>     with him as of January 1, 2006, controlled <font color="blue">approximately</font> 56dtta8prca of our common     stock</td>
    </tr>
    <tr>
      <td>The <font color="blue">administrative services</font> <font color="blue">agreement</font> has <font color="blue">terms no less</font> favorable     than those that we would have <font color="blue"><font color="blue">entered into</font> with</font> an un<font color="blue">affiliated</font> third party,     and  the  <font color="blue">agreement</font>  was <font color="blue">approved by</font> a majority of the in<font color="blue">dependent</font> and     <font color="blue">disinterested members</font> of our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">executive officers</font> and other <font color="blue">key personnel</font> are critical to our business,     and our <font color="blue">future success depends on</font> our ability to retain them</td>
    </tr>
    <tr>
      <td>We are highly <font color="blue">dependent</font> on the <font color="blue">principal members</font> of our <font color="blue">management</font> and     scientific team, <font color="blue">particularly</font>, Mr</td>
    </tr>
    <tr>
      <td>In order to pursue our product <font color="blue">development</font>,     marketing and <font color="blue">commercialization</font> plans, we will need to hire <font color="blue">additional</font>     personnel  with experience in clinical testing, <font color="blue">government</font> regulation,     <font color="blue">manufacturing</font>, marketing and business <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We may not be able to     attract  and  retain  personnel  on acceptable <font color="blue">terms given</font> the intense     <font color="blue">competition</font> for such personnel among bio<font color="blue">technology</font>, <font color="blue">pharmaceutical</font> and     healthcare companies, universities and non-profit research institutions</td>
    </tr>
    <tr>
      <td>We     have no employment <font color="blue">agreement</font>s with any of our <font color="blue">executive officers</font> and while     we have employment <font color="blue">agreement</font>s with certain of our employees, all of our     employees are at-will employees who <font color="blue">may terminate</font> their <font color="blue">employment at</font> any     time</td>
    </tr>
    <tr>
      <td>We do not currently have                                         30       _________________________________________________________________    [79]Table of <font color="blue">Contents       </font><font color="blue">key personnel</font> insurance on any of our officers or employees</td>
    </tr>
    <tr>
      <td>The loss of any     of our <font color="blue">key personnel</font>, or the <font color="blue">inability</font> to attract and retain qualified     personnel,  may  <font color="blue"><font color="blue">significant</font>ly</font> delay or prevent the <font color="blue">achievement</font> of our     research, <font color="blue">development</font> or business <font color="blue">objectives</font> and could <font color="blue">materially</font> <font color="blue">adversely</font>     affect our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on <font color="blue">third parties</font></font> to <font color="blue">manufacture</font> the <font color="blue">compounds used</font> in our trials,     and we intend to <font color="blue">rely on them</font> for the <font color="blue">manufacture</font> of any <font color="blue">approved products</font>     for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>If these <font color="blue">third parties</font> do not <font color="blue">manufacture</font> our product     <font color="blue">candidates</font> in <font color="blue">sufficient quantities</font> and at an acceptable cost, clinical     <font color="blue">development</font> and <font color="blue">commercialization</font> of our <font color="blue">product <font color="blue">candidates</font></font> could be     delayed, prevented or impaired</td>
    </tr>
    <tr>
      <td>We have no <font color="blue">manufacturing</font> facilities, and we have no experience in the     clinical or commercial-scale <font color="blue">manufacture</font> of drugs or in <font color="blue">designing drug</font>     <font color="blue">manufacturing</font> processes</td>
    </tr>
    <tr>
      <td>Certain specialized <font color="blue">manufacture</font>rs provide us with     modified  and  unmodified <font color="blue">pharmaceutical</font> compounds, including finished     products, for use in our preclinical and <font color="blue">clinical studies</font></td>
    </tr>
    <tr>
      <td>We do not have     any short-term or long-term <font color="blue">manufacturing</font> <font color="blue">agreement</font>s with any of these     <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>If we fail to contract for <font color="blue">manufacturing</font> on acceptable terms     or if third-party <font color="blue">manufacture</font>rs do not perform as we expect, our <font color="blue">development</font>     <font color="blue">programs could</font> be <font color="blue">materially</font> <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Any <font color="blue">such delays could</font> cause our prospects to suffer <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td>We intend to <font color="blue">rely on <font color="blue">third parties</font></font> to <font color="blue">manufacture</font> some or all of our     products that reach <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>We believe that there are a variety     of <font color="blue">manufacture</font>rs that we may be able to retain to produce these products</td>
    </tr>
    <tr>
      <td>However, once we retain a <font color="blue">manufacturing</font> source, if our <font color="blue">manufacture</font>rs do not     perform  in  a  satisfactory  manner, we may not be able to develop or     <font color="blue">commercialize</font> <font color="blue">potential product</font>s as planned</td>
    </tr>
    <tr>
      <td>Failure by our third-party <font color="blue">manufacture</font>rs to <font color="blue">comply with</font> the <font color="blue">regulatory</font>     <font color="blue">guidelines set forth by</font> the <font color="blue">FDA and DEA </font><font color="blue">with respect</font> to our product     <font color="blue">candidates</font> could delay or prevent the <font color="blue">completion</font> of <font color="blue">clinical trials</font>, the     approval of any <font color="blue">product <font color="blue">candidates</font></font> or the <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>Our reliance on third-party <font color="blue">manufacture</font>rs exposes us to the following     <font color="blue">additional</font> risks, any of <font color="blue">which could delay</font> or prevent the <font color="blue">completion</font> of our     <font color="blue">clinical trials</font>, the approval of our <font color="blue">product <font color="blue">candidates</font></font> by the FDA or other     <font color="blue">regulatory</font> agencies or the <font color="blue">commercialization</font> of our products, result in     <font color="blue">higher costs</font> or <font color="blue">deprive us</font> of <font color="blue">potential product</font> revenues:         •  <font color="blue">Manufacturers </font>are obligated to operate in <font color="blue">accordance with</font> FDA-mandated     current good <font color="blue">manufacturing</font> practice (cGMP) <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>A failure of any of     our third-party <font color="blue">manufacture</font>rs to establish and follow cGMP <font color="blue"><font color="blue">requirement</font>s</font> and     to document their adherence to <font color="blue">such practices may lead</font> to <font color="blue">significant</font> delays     in the <font color="blue">availability</font> of material for <font color="blue">clinical trials</font>, may delay or prevent     filing or approval of marketing <font color="blue">application</font>s for our products, and may cause     delays or <font color="blue">interruptions</font> in the <font color="blue">availability</font> of our products for commercial     <font color="blue"><font color="blue">distribution</font> following</font> FDA approval</td>
    </tr>
    <tr>
      <td>•  <font color="blue">Replacing </font>our third-party <font color="blue">manufacture</font>rs or contracting with <font color="blue">additional</font>     <font color="blue">manufacture</font>rs may require re-validation of the <font color="blue">manufacturing</font> processes and     procedures in <font color="blue">accordance with</font> cGMP and <font color="blue">compliance with supplemental approval</font>     <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>Any such <font color="blue">necessary</font> re-validation and <font color="blue">supplemental approvals</font>     may be costly and time- consuming</td>
    </tr>
    <tr>
      <td>Drug  <font color="blue">manufacture</font>rs are subject to <font color="blue">ongoing periodic unannounced</font>     <font color="blue">inspections by</font> the FDA, the DEA and <font color="blue">corresponding</font> state and foreign agencies     to ensure strict compliance with cGMP <font color="blue"><font color="blue">requirement</font>s</font> and other <font color="blue"><font color="blue">requirement</font>s</font>     under Federal drug laws, other <font color="blue">government</font> <font color="blue">regulations</font> and <font color="blue">corresponding</font>     <font color="blue">foreign standards</font></td>
    </tr>
    <tr>
      <td>If our third-party <font color="blue">manufacture</font>rs or we fail to comply     with applicable <font color="blue">regulations</font>, sanctions could be <font color="blue">imposed on us</font>, including     fines, injunctions, civil penalties, failure by the <font color="blue">government</font> to grant     <font color="blue">marketing approval</font> of drugs, delays, suspension or withdrawal of approvals,     seizures  or  recalls  of product, operating <font color="blue">restrictions</font> and criminal     <font color="blue">prosecutions</font></td>
    </tr>
    <tr>
      <td>We may need <font color="blue">additional</font> capital in the future</td>
    </tr>
    <tr>
      <td>If <font color="blue">additional</font> capital is not     available or is <font color="blue">available at unattractive terms</font>, we may be forced to delay,     reduce the scope of or eliminate our research and <font color="blue">development</font> programs,     reduce our <font color="blue">commercialization</font> efforts or curtail our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>31       _________________________________________________________________    [80]Table of <font color="blue">Contents       </font>      In order to develop and bring our <font color="blue">product <font color="blue">candidates</font></font> to market, we     must commit substantial resources to costly and time-consuming research,     preclinical and <font color="blue">clinical trials</font> and <font color="blue">marketing <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>We anticipate that     our <font color="blue">existing cash</font> and <font color="blue">cash equivalents</font> and short-term <font color="blue">investment</font>s will     <font color="blue">enable us</font> to maintain our current planned <font color="blue">operations</font> for at least the next     18 months</td>
    </tr>
    <tr>
      <td>We anticipate using our cash and <font color="blue">cash equivalents</font> and short-term     <font color="blue">investment</font>s to <font color="blue">fund further research</font> and <font color="blue">development</font> <font color="blue">with respect</font> to our     lead <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We may, however, need to raise <font color="blue">additional</font> funding     sooner  if our business or <font color="blue">operations</font> change in a manner that consumes     <font color="blue">available resources</font> more <font color="blue">rapidly than</font> we anticipate, which may include if we     are granted <font color="blue">Fast Track </font>status <font color="blue">with respect</font> to any of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue"><font color="blue">requirement</font>s</font>  for <font color="blue">additional</font> capital <font color="blue">will depend on</font> many factors,     including:         •  successful <font color="blue">commercialization</font> of our <font color="blue">product <font color="blue">candidates</font></font>;         •  continued progress of research and <font color="blue">development</font> of <font color="blue">product <font color="blue">candidates</font></font>     utilizing our Carrierwave <font color="blue">technology</font>;         •  the time and <font color="blue">costs involved</font> in obtaining <font color="blue">regulatory</font> approval for our     <font color="blue">product <font color="blue">candidates</font></font>;         •  <font color="blue">costs associated with protecting</font> our <font color="blue"><font color="blue">intellectual</font> <font color="blue">property rights</font></font>;         •  <font color="blue">development</font> of marketing and <font color="blue">sales <font color="blue">capabilities</font></font>;         •  payments received under our <font color="blue">collaboration</font> <font color="blue">agreement</font>s with Shire and any     future <font color="blue">collaborative</font> <font color="blue">agreement</font>s, if any; and         •  <font color="blue">market acceptance</font> of our products</td>
    </tr>
    <tr>
      <td><font color="blue">As of January </font>1, 2006, we have no committed <font color="blue">additional</font> sources of     capital</td>
    </tr>
    <tr>
      <td>To the extent our capital resources are insufficient to meet future     capital <font color="blue"><font color="blue">requirement</font>s</font>, we will need to raise <font color="blue">additional</font> funds to continue the     <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We anticipate that we will need     <font color="blue">significant</font> <font color="blue">additional</font> funds in order for us to <font color="blue">commercialize</font> NRP104 and     continue the <font color="blue">development</font> of NRP290 and other <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>To the extent we raise     <font color="blue">additional</font> capital through the sale of equity securities, the issuance of     those securities could result in dilution to our <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>In addition,     if we obtain <font color="blue">debt financing</font>, a substantial portion of our operating cash     flow may be dedicated to the payment of principal and <font color="blue">interest on such</font>     indebtedness, thus limiting funds available for our business <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If     <font color="blue">adequate funds</font> are not available, we may be required to delay, reduce the     scope of or eliminate our research and <font color="blue">development</font> programs, reduce our     <font color="blue">commercialization</font> efforts or curtail our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, we may be     required to obtain funds through <font color="blue">arrangements</font> with <font color="blue"><font color="blue">collaborative</font> partners</font>,     such  as  our  <font color="blue">agreement</font>s with Shire, or others that may require us to     <font color="blue">relinquish</font> rights to <font color="blue">technologies</font>, <font color="blue">product <font color="blue">candidates</font></font> or products that we     would otherwise seek to develop or <font color="blue">commercialize</font> ourselves or license rights     to <font color="blue">technologies</font>, <font color="blue">product <font color="blue">candidates</font></font> or products on terms that are less     favorable to us than might otherwise be available</td>
    </tr>
    <tr>
      <td>Even if we obtain <font color="blue">regulatory</font> approval to market our <font color="blue">product <font color="blue">candidates</font></font>, our     <font color="blue">product <font color="blue">candidates</font></font> may not be <font color="blue">accepted by</font> the market</td>
    </tr>
    <tr>
      <td>Even  if  we  obtain  <font color="blue">regulatory</font> approval to market our product     <font color="blue">candidates</font>, our <font color="blue">product <font color="blue">candidates</font></font> may not gain <font color="blue">market acceptance</font> among     physicians, patients, healthcare payors and the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>The     degree of <font color="blue">market acceptance</font> of any <font color="blue">pharmaceutical</font> product that we develop     <font color="blue">will depend on</font> a number of factors, including:         •  cost-<font color="blue"><font color="blue">effective</font>ness</font>;         •  the safety and <font color="blue"><font color="blue">effective</font>ness</font> of our products, including any potential     side effects, as compared to <font color="blue">alternative products</font> or <font color="blue">treatment methods</font>;         •  the timing of <font color="blue">market entry as compared</font> to <font color="blue">competitive</font> products;         •  the rate of adoption of our <font color="blue">products by doctors</font> and nurses;         •  <font color="blue">product labeling</font> or <font color="blue">product insert</font> required by the FDA for each of our     products;                                         32       _________________________________________________________________    [81]Table of <font color="blue">Contents       </font>  •  <font color="blue">de<font color="blue">termination</font></font> of scheduled or <font color="blue">unscheduled status by</font> the FDA and DEA;         •  <font color="blue"><font color="blue">reimbursement</font> policies</font> of <font color="blue">government</font> and third-party payors;         •  <font color="blue"><font color="blue">effective</font>ness</font> of our sales, marketing and <font color="blue"><font color="blue">distribution</font> <font color="blue">capabilities</font></font> and     the <font color="blue"><font color="blue">effective</font>ness</font> of <font color="blue">such <font color="blue">capabilities</font></font> of our <font color="blue"><font color="blue">collaborative</font> partners</font>; and         •  <font color="blue">unfavorable publicity concerning</font> our products or any similar products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font>, if <font color="blue">successfully</font> developed, will <font color="blue">compete with</font> a     number  of  products <font color="blue">manufacture</font>d and marketed by major <font color="blue">pharmaceutical</font>     companies, bio<font color="blue">technology</font> companies and <font color="blue">manufacture</font>rs of <font color="blue">generic drugs</font></td>
    </tr>
    <tr>
      <td>Physicians, patients, third-party payors and the <font color="blue">medical community</font>     may not accept and utilize any of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Physicians </font>may not     be  inclined  to prescribe the drugs created utilizing our Carrierwave     <font color="blue">technology</font> unless our <font color="blue">drugs bring</font> substantial and demonstrable <font color="blue">advantages</font>     over  other  drugs <font color="blue">currently marketed</font> for the <font color="blue">same <font color="blue">indications</font></font></td>
    </tr>
    <tr>
      <td>If our     products do not achieve <font color="blue">market acceptance</font>, we will not be able to generate     <font color="blue">significant</font> revenues or <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>If we fail to establish marketing, sales and <font color="blue"><font color="blue">distribution</font> <font color="blue">capabilities</font></font>, or     fail to <font color="blue">enter into</font> <font color="blue">arrangements</font> <font color="blue">with <font color="blue">third parties</font></font> to do this on our behalf,     we will not be able to create a market for our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Currently,  we do not have any sales, marketing or <font color="blue">distribution</font>     <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>In order to <font color="blue">generate sales</font> of any <font color="blue">product <font color="blue">candidates</font></font> that     receive <font color="blue">regulatory</font> approval, we must either acquire or develop an internal     marketing and <font color="blue">sales force with technical expertise</font> and <font color="blue">with supporting</font>     <font color="blue"><font color="blue">distribution</font> <font color="blue">capabilities</font></font> or make <font color="blue">arrangements</font> <font color="blue">with <font color="blue">third parties</font></font> to perform     these  services for us, as we did in our <font color="blue"><font color="blue">collaboration</font> with</font> Shire</td>
    </tr>
    <tr>
      <td>The     <font color="blue">acquisition</font> or <font color="blue">development</font> of a sales and <font color="blue">distribution</font> <font color="blue">infrastructure</font> would     require  substantial  resources, which may divert the attention of our     <font color="blue">management</font> and <font color="blue">key personnel</font> and defer our product <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>To     the extent that we <font color="blue">enter into</font> marketing and sales <font color="blue">arrangements</font> with other     companies, our revenues <font color="blue">will depend on</font> the efforts of others</td>
    </tr>
    <tr>
      <td>If  we fail to develop sales, marketing and     <font color="blue">distribution</font> channels, or <font color="blue">enter into</font> <font color="blue">arrangements</font> <font color="blue">with <font color="blue">third parties</font></font>, we     will experience delays in <font color="blue">product sales</font> and <font color="blue">incur increased costs</font></td>
    </tr>
    <tr>
      <td>In the event that we are successful in bringing any products to market, our     revenues may be <font color="blue">adversely</font> affected if we fail to obtain acceptable prices or     adequate <font color="blue">reimbursement</font> for our <font color="blue">products from</font> third-party payors</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> <font color="blue">pharmaceutical</font> products <font color="blue">successfully</font> may     depend in part on the <font color="blue">availability</font> of <font color="blue">reimbursement</font> for our <font color="blue">products from</font>:         •  <font color="blue">government</font> and <font color="blue">health administration authorities</font>;         •  <font color="blue">private health insurers</font>; and         •  other third-party payors, including Medicare</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the <font color="blue">availability</font> of <font color="blue">reimbursement</font> for <font color="blue">newly approved</font>     health  care  products</td>
    </tr>
    <tr>
      <td>Third-party  payors,  including Medicare, are     <font color="blue">challenging</font> the <font color="blue">prices charged</font> for <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td><font color="blue">Government     </font>and other third-party payors increasingly are <font color="blue">limiting both coverage</font> and the     level of <font color="blue">reimbursement</font> for new drugs</td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">insurance coverage may</font> not     be available to patients for any of our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">continuing efforts</font> of <font color="blue">government</font> and third-party payors to contain     or reduce the costs of <font color="blue">health care may limit</font> our commercial <font color="blue">opportunity</font></td>
    </tr>
    <tr>
      <td>If     <font color="blue">government</font> and other third-party payors do not <font color="blue">provide adequate coverage</font> and     <font color="blue">reimbursement</font> for any <font color="blue">prescription product</font> we bring to market, doctors may     not <font color="blue">prescribe them</font> or <font color="blue">patients may ask</font> to have their <font color="blue">physicians prescribe</font>     <font color="blue">competing drugs with</font> more favorable <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>In some <font color="blue">foreign markets</font>,     pricing and <font color="blue">profitability</font> of prescription <font color="blue">pharmaceutical</font>s are subject to     <font color="blue">government</font> control</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, we expect that <font color="blue">there <font color="blue">will continue</font></font>     to be federal and state proposals for similar controls</td>
    </tr>
    <tr>
      <td>In addition, we     expect that <font color="blue">increasing emphasis on managed care</font> in the <font color="blue">United                                         </font>33       _________________________________________________________________    [82]Table of <font color="blue">Contents       </font>States  <font color="blue">will continue</font> to <font color="blue">put pressure on</font> the pricing of <font color="blue">pharmaceutical</font>     products</td>
    </tr>
    <tr>
      <td>Cost <font color="blue">control initiatives could decrease</font> the price that we receive     for any products in the future</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">cost control initiatives could</font>     impair our ability to <font color="blue">commercialize</font> our products and our ability to earn     <font color="blue">revenues from</font> this <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>We could be forced to pay substantial <font color="blue">damage awards</font> if <font color="blue">product <font color="blue">liability</font></font>     claims that may be brought <font color="blue">against us</font> are successful</td>
    </tr>
    <tr>
      <td>The use of any of our <font color="blue">product <font color="blue">candidates</font></font> in <font color="blue">clinical trials</font>, and the     sale  of  any <font color="blue">approved products</font>, may expose us to <font color="blue">liability</font> claims and     <font color="blue">financial losses</font> resulting from the use or sale of our products</td>
    </tr>
    <tr>
      <td>We have     obtained limited <font color="blue">product <font color="blue">liability</font></font> insurance coverage for our clinical     trials of dlra10 million per occurrence and in the aggregate, subject to a     deductible of dlra50cmam000 per occurrence and dlra500cmam000 per year in the aggregate</td>
    </tr>
    <tr>
      <td>However, <font color="blue">such insurance may</font> not be adequate to cover any claims made against     us</td>
    </tr>
    <tr>
      <td>In addition, we may not be able to maintain <font color="blue">insurance coverage at</font> a     <font color="blue">reasonable cost</font> or in <font color="blue">sufficient amounts</font> or scope to <font color="blue">protect us against</font>     losses</td>
    </tr>
    <tr>
      <td>We <font color="blue">use <font color="blue"><font color="blue">hazardous</font> chemicals</font></font> in our business</td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font>claims relating to     improper handling, storage or disposal of these <font color="blue">chemicals could</font> be time     consuming and costly</td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> processes involve the <font color="blue">controlled use</font> of     <font color="blue"><font color="blue">hazardous</font> chemicals</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">hazardous</font> chemicals</font> are reagents and solvents     <font color="blue">typically found</font> in a chemistry <font color="blue">laboratory</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> also produce     <font color="blue"><font color="blue">hazardous</font> <font color="blue">waste products</font></font></td>
    </tr>
    <tr>
      <td>Federal, state and <font color="blue">local laws</font> and <font color="blue">regulations</font>     govern the use, <font color="blue">manufacture</font>, storage, handling and disposal of <font color="blue">hazardous</font>     materials</td>
    </tr>
    <tr>
      <td>While we attempt to <font color="blue">comply with</font> all <font color="blue"><font color="blue">environmental</font> laws</font> and     <font color="blue">regulations</font>, including those relating to the outsourcing of the disposal of     all <font color="blue"><font color="blue">hazardous</font> chemicals</font> and <font color="blue">waste products</font>, we <font color="blue">cannot eliminate</font> the risk of     <font color="blue">accidental contamination from</font> or discharge of <font color="blue">hazardous</font> materials and any     <font color="blue">resultant injury</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with <font color="blue"><font color="blue">environmental</font> laws</font> and <font color="blue">regulations</font> may be     expensive</td>
    </tr>
    <tr>
      <td>Current or future <font color="blue">environmental</font> <font color="blue">regulations</font> may impair our     research, <font color="blue">development</font> or production efforts</td>
    </tr>
    <tr>
      <td>We might have to pay civil     damages in the event of an improper or <font color="blue">unauthorized release</font> of, or exposure     of <font color="blue">individuals</font> to, <font color="blue">hazardous</font> materials</td>
    </tr>
    <tr>
      <td>We are not <font color="blue">insured against</font> these     <font color="blue">environmental</font> risks</td>
    </tr>
    <tr>
      <td>In our <font color="blue"><font color="blue">collaboration</font>s</font> <font color="blue">with <font color="blue">third parties</font></font>, they <font color="blue">might also</font> work with     <font color="blue">hazardous</font> materials in <font color="blue"><font color="blue">connection</font> with</font> our <font color="blue"><font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>We may agree to     indemnify our <font color="blue">collaborators</font> in some <font color="blue">circumstances</font> against damages and other     <font color="blue">liabilities</font> arising out of <font color="blue">development</font> <font color="blue">activities</font> or products produced in     <font color="blue"><font color="blue">connection</font> with</font> these <font color="blue"><font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>If Shire, our <font color="blue"><font color="blue">collaboration</font> partner on</font> NRP104, or any other <font color="blue">collaborative</font>     partners we retain, do not satisfy their <font color="blue">obligations</font>, we will be unable to     develop our partnered <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Currently, we have <font color="blue">entered into</font> a <font color="blue">collaborative</font> <font color="blue">agreement</font> with <font color="blue">Shire     </font>relating to the global <font color="blue">commercialization</font> of NRP104 for treatment of ADHD and     other  potential  <font color="blue">indications</font></td>
    </tr>
    <tr>
      <td>This  <font color="blue">collaboration</font>  includes  product     <font color="blue">development</font>, <font color="blue">manufacturing</font>, marketing and sales</td>
    </tr>
    <tr>
      <td>We do not have day-to-day     <font color="blue">control over</font> the <font color="blue">activities</font> of Shire <font color="blue">with respect</font> to NRP104</td>
    </tr>
    <tr>
      <td>In the event we     <font color="blue">enter into</font> any other <font color="blue">collaborative</font> <font color="blue">agreement</font>s, we may not have day-to-day     <font color="blue">control over</font> the <font color="blue">activities</font> of such <font color="blue">collaborative</font> partner <font color="blue">with respect</font> to     any of these <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Shire or any other <font color="blue">collaborative</font> partner     may not fulfill its <font color="blue">obligations</font> under these <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>If Shire or any     other  <font color="blue">collaborative</font> partner fails to fulfill its <font color="blue">obligations</font> under an     <font color="blue">agreement</font>  with  us, we may be unable to assume the <font color="blue">development</font> of the     <font color="blue">products covered by</font> that <font color="blue">agreement</font> or <font color="blue">enter into</font> alternative <font color="blue">arrangements</font>     with  a  third  party</td>
    </tr>
    <tr>
      <td>In  addition,  we  <font color="blue">may encounter delays</font> in the     <font color="blue">commercialization</font>  of the <font color="blue">product candidate</font> that is the subject of the     <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Accordingly, our ability to receive any <font color="blue">revenue from</font> the product     <font color="blue">candidates</font> covered by these <font color="blue">agreement</font>s will be <font color="blue">dependent</font> on the efforts of     our <font color="blue">collaborative</font> partner</td>
    </tr>
    <tr>
      <td>We <font color="blue">could also become involved</font> in <font color="blue">disputes with</font>     Shire or another <font color="blue">collaborative</font> partner, which could lead to delays in or     <font color="blue">termination</font>  of  our  <font color="blue">development</font>  and  <font color="blue">commercialization</font> programs and     time-consuming and expensive <font color="blue">litigation</font> or <font color="blue">arbitration</font></td>
    </tr>
    <tr>
      <td>In addition, any     <font color="blue">such dispute could diminish</font> our <font color="blue">collaborators</font>’ commitment to us and reduce     the resources they devote to developing and <font color="blue">commercializing</font> our products</td>
    </tr>
    <tr>
      <td><font color="blue">Conflicts </font>or <font color="blue">disputes with</font> our <font color="blue">collaborators</font>, and <font color="blue">competition</font> from them,     could harm our <font color="blue">relationships</font> with our other <font color="blue">collaborators</font>, restrict our     ability to enter future <font color="blue">collaboration</font> <font color="blue">agreement</font>s and delay the research,     <font color="blue">development</font>  or  <font color="blue">commercialization</font>  of  our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If any     <font color="blue">collaborative</font> partner terminates or                                         34       _________________________________________________________________    [83]Table of <font color="blue">Contents       </font>breaches its <font color="blue">agreement</font>, or <font color="blue">otherwise fails</font> to complete its <font color="blue">obligations</font> in a     <font color="blue">timely manner</font>, our chances of <font color="blue">successfully</font> developing or <font color="blue">commercializing</font>     these <font color="blue">product <font color="blue">candidates</font></font> would be <font color="blue">materially</font> and <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>We may     not be able to <font color="blue">enter into</font> other <font color="blue">collaborative</font> <font color="blue">agreement</font>s with partners on     terms favorable to us, or at all</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to <font color="blue">enter into</font> <font color="blue">collaborative</font>     <font color="blue">arrangements</font> with <font color="blue"><font color="blue">collaborative</font> partners</font>, or our failure to maintain such     <font color="blue">arrangements</font>, would limit the number of <font color="blue">product <font color="blue">candidates</font></font> that we could     develop and ultimately, decrease our sources of any <font color="blue">future revenues</font></td>
    </tr>
    <tr>
      <td>Certain provisions of Virginia law, and our amended and <font color="blue">restated articles</font> of     <font color="blue">incorporation</font> and amended and <font color="blue">restated bylaws could</font> make it more <font color="blue">difficult</font>     for our <font color="blue">shareholders</font> to remove our board of <font color="blue">directors</font> and <font color="blue">management</font></td>
    </tr>
    <tr>
      <td><font color="blue">Certain  </font>provisions  of Virginia law, the state in which we are     <font color="blue">incorporated</font>, and our amended and <font color="blue">restated articles</font> of <font color="blue">incorporation</font> and     amended  and  restated  bylaws  could  make  it more <font color="blue">difficult</font> for our     <font color="blue">shareholders</font>, should they choose to do so, to remove our board of <font color="blue">directors</font>     or <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>These provisions include:         •  a <font color="blue">provision allowing</font> our board of <font color="blue">directors</font> to <font color="blue">issue preferred stock</font>     <font color="blue">with rights senior</font> to those of the <font color="blue">common stock</font> without any vote or action     by the holders of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The issuance of <font color="blue">preferred stock could</font>     <font color="blue">adversely</font> affect the rights and powers, including <font color="blue">voting rights</font>, of the     holders of <font color="blue">common stock</font>;         •  a <font color="blue">provision allowing</font> the removal of <font color="blue">directors</font> only for cause;         •  the <font color="blue">requirement</font> in our bylaws that <font color="blue">shareholders</font> provide advance notice     when nominating our <font color="blue">directors</font> or submitting other <font color="blue">shareholder proposals</font>; and          •  the <font color="blue">inability</font> of <font color="blue">shareholders</font> to convene a <font color="blue">shareholders</font>’ meeting     without the chairman of the board, the <font color="blue">chief executive officer</font> or a majority     of the board of <font color="blue">directors</font> first calling the meeting</td>
    </tr>
  </tbody>
</table>